Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI)\r\n* NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
No lytic lesions on skeletal survey and whole body positron emission tomography (PET)/computed tomography (CT) other than a single lesion associated with solitary bone plasmacytoma
Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable metastatic disease per RECIST 1.1
Measurable disease >= 1.5 cm seen on computed tomography (CT) scan and fludeoxyglucose F-18 (FDG) avid disease on positron emission tomography (PET) scan
No evidence of metastases based on radiological imaging (computed tomography [CT], MRI or positron emission tomography [PET]/CT including chest abdomen and pelvis)
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
Measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT (PET/CT fusion); skins lesions can be used if the area is greater than or equal to 2 cm in at least one diameter and photographed with a ruler
Patients must have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan
?1 bone lesion identifiable by radiograph, computed tomography (CT), positron emission tomography - computed tomography (PET-CT), or magnetic resonance imaging (MRI).
Patients who cannot undergo neither MRI nor computed tomography (CT) evaluation/examination
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of at least 1.5 cm in minimum dimension by computed tomography (CT) scan with contrast, as assessed by the site radiologist
Patients with measurable disease defined as at least one of the following:\r\n* For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at least one diameter and measured with a ruler\r\n* Plasma cell count >= 0.5 X 10^9/L or 5 percent of the peripheral blood white cells\r\n* Plasma cell count if determined by flow cytometry, >= 200/150,000 events
Absence of lytic bone lesion on X-ray, computed tomography (CT), or positron emission tomography (PET)/CT and not more than 1 lesion on spinal magnetic resonance imaging (MRI) (NOTE: at the discretion of the investigator, PET/CT may replace MRI in patients who have a contraindication to MRI)
Have measurable disease based on defined as at least one lesion that can be accurately measured in at least two dimensions with a spiral computed tomography (CT) scan, positron emission tomography (PET)/CT scan, or magnetic resonance imaging (MRI). Minimum measurement of > 1.5 cm in longest diameter by > 1.0 cm in short axis.
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Patients with systemic T cell lymphoma of any stage and any subtypes; patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment; bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Patients must have systemic cross-sectional imaging (positron emission tomography [PET]/computed tomography [CT] or CT of chest, abdomen, and pelvis) which shows no evidence of metastatic disease
Stage M1\r\n* Metastatic disease can be documented by bone scan or computed tomography (CT) scan or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT or the combination of these tests
Patients who cannot undergo MRI or single-photon emission computed tomography (SPECT)/computed tomography (CT)
Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer
Have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
Neck computed tomography (CT) and/or neck magnetic resonance imaging (MRI), and whole body positron emission tomography (PET)-CT
Staging computed tomography (CT) chest, abdomen, pelvis (CAP) or positron emission tomography (PET)/CT shows no evidence of metastatic disease
Patients are required to have computed tomography (CT) neck and chest or positron emission tomography (PET)/CT and have no documented evidence of distant metastases
Measurable nodal disease by computed tomography (CT)
Subject who are willing to undergo a bone marrow aspiration and biopsy and computed tomography (CT) scan for disease burden assessment
Patients must have measurable disease, defined as at least one lesion that is > 15 mm (1.5 cm) in the longest axis on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral computed tomography [CT]), positron emission tomography (PET)-CT or magnetic resonance imaging (MRI)
Stage II-IV disease; participant will need measurable disease by computed tomography (CT) or positron emission tomography (PET) scans if enrolled in the dose-expansion cohort
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen/pelvis or CT/positron emission tomography (PET) scans
Patient must have measurable disease > 1.5 cm evidenced by computed tomography (CT) of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT), or computed tomography (CT), of at least 1.5 cm within the last 21 days before the start of IP treatment.
The treated lesion must be within 2 cm of the abdominal gastrointestinal tract (abdominal esophagus to sigmoid colon) on the basis of cross sectional imaging study such as computed tomography (CT), positron emission tomography (PET)/CT, or MRI
Presence of radiographically measurable disease (defined as the presence of a >= 1.0 cm lesion, as measured in the longest dimension by computed tomography [CT] scan or positron emission tomography [PET]/CT scan or magnetic resonance imaging [MRI] scan)
Metastatic breast cancer not amenable to potentially curative surgery; patients must have disease that is measurable and/or non-measurable as defined by RECIST 1.1 criteria (assessed by computed tomography [CT] scan chest/abdomen/pelvis with contrast or fludeoxyglucose [FDG] positron emission tomography [PET]-CT scan obtained within 4 weeks of registration)
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT) of at least 1.5 cm
Subjects with more than one site of distant metastatic disease (beyond the head and neck) as evidenced by computed tomography (CT) scan or positron emission tomography (PET)/CT or biopsy\r\n* A subject with a single lung nodule (deemed cancerous by PET/CT or biopsy) will not be excluded
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Presence of measurable disease by computed tomography (CT) scan
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and dimensional measurable disease of at least 1.5 cm as documented by radiographic technique (spiral computed tomography [CT] preferred)
Disease status requirement: Measurable disease defined as the presence of ? 1 nodal lesion that measures ? 1.5 cm in a single dimension as assessed by X-ray Computed Tomography (CT) (Positron Emission Tomography (PET/CT), or magnetic resonance imaging [MRI]
Have baseline imaging within 6 weeks of enrollment (computed tomography [CT], magnetic resonance [MR] or positron emission tomography [PET]/CT imaging) and have measurable disease on physical examination or imaging studies; any lesion >= 1.5 cm in long axis dimension is considered measurable
Have measurable nodal disease, including at least 1 disease site measuring 1.5 cm in longest dimension on computed tomography (CT) or fludeoxyglucose (FDG)-positron emission tomography (PET)
Patients must have metabolically active (positron emission tomography [PET] scan positive) measurable disease (defined as lesions greater than 1.5 cm long axis that can be accurately measured in two dimensions by computed tomography [CT])
Subjects must be able to undergo either MRI or computed tomography (CT)
Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more); Note: CT scans remain the standard for evaluation of nodal disease
No distant metastasis by positron emission tomography (PET)/computed tomography (CT); PET/CT will be done at time of simulation in the treatment position
The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib
Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by a diagnostic quality computed tomography (CT) scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
Bone marrow involvement based on computed tomography (CT) or PET scan at screening
History of severe reaction to contrast-enhanced computed tomography (CT) scan
Patients with solid tumors must have measurable or evaluable (for neuroblastoma and Ewing sarcoma) disease. Tumor assessment will be done via computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion. Bone scans (if clinically indicated) should be obtained within ? 4 weeks prior to the start of treatment.
Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) (dedicated CT or the CT portion of a positron emission tomography [PET]/CT) or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of >= 1.5 cm \r\n* NOTE: Skin lesions can be used if the area is >= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
Patients must have measurable disease, defined as at least one lesion that is ? 15 mm (? 1.5 cm) in the longest axis on cross-sectional imaging and measurable in two perpendicular dimensions per spiral computed tomography (CT) scan or positron-emission tomography (PET)-CT scan
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment
Staging computed tomography (CT) scans done prior to enrollment
Pre-operative scans including MRI/computed tomography (CT) neck and, CT chest with contrast; if contrast is contraindicated, staging positron emission tomography (PET) or PET-CT is acceptable although high quality/diagnostic cross-sectional imaging of the head and neck area is recommended
Melanoma cohort only: measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT; NOTE: disease that is measurable by physical examination only is not eligible
If remission status < 1 year for NHL, complete remission documented by computed tomography (CT) or positron emission tomography (PET)-CT scan within 3 months of study entry
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
Patients are preferred to have either a tumor mass amenable to core needle biopsy during the dosimetry phase, or a measurable tumor mass with at least one site of involvement measuring 2.5 cm in largest dimension on computed tomography (CT) imaging for purposes of planar and/or single-photon emission computed tomography (SPECT)/CT tumor dosimetry
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic; laboratory parameters are not acceptable as the only evidence of disease
(B) Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, Computed tomography (CT), or PET-CT
Measurable nodal disease by computed tomography (CT)
Patients must have measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
Bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Patients must be in complete remission at D60-180 after AHCT as evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter\r\nby computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Patients with history of second malignancy are eligible if they have documentation of disease stability, off therapy, based on computed tomography (CT) scan or other measures for the 6 months prior to entry in core
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Participants must have had PET-computed tomography (CT) for restaging after salvage therapy and before ASCT
Subject has evidence of pre-existing idiopathic pulmonary fibrosis on computed tomography (CT) scan at baseline
Patients with measurable disease; patients with non-measurable but evaluable disease may be eligible after discussion with the principal investigator (PI); baseline measurements and evaluations must be obtained within 6 weeks of registration to the study; abnormal positron emission tomography (PET)/computed tomography (CT) scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-CT (PET-CT) OR
Measurable disease for phase IIa portion only \r\n* Lymphoma (includes CTCL patients who are without evidence of the disease in the skin): computed tomography (CT) or positron emission tomography (PET)/CT by modified Cheson criteria with incorporation of PET\r\n* CTCL: modified severity weighted assessment (mSWAT) > 0, or absolute Sezary count >= 1000 cells/uL
Radiographic evidence (computed tomography [CT], magnetic resonance [MR], or positron emission tomography [PET] CT) consistent with osseous metastatic disease on CT, MR, or PET CT obtained within 4 weeks of treatment will be used for pre-study treatment delivery; the gross tumor volume (GTV) of the target lesions will be determined from this radiographic study and must be =< 250 cubic centimeters\r\n* NOTE: patient is still eligible if a diagnostic image set is not available within 4 weeks of treatment if the patient will undergo a kilo voltage CT (kVCT) simulation in the Department of Radiation Oncology with contouring directly onto this image set
Chemosensitive disease as defined by at least a partial response to salvage therapy by PET/computed tomography (CT) criteria
Measurable disease: lesions that can be accurately measured in at least two dimensions as >= 1.0 x 1.0 cm by computerized tomography (CT), PET/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI)
For patients with solid malignancies and lymphoma, radiographically detectable (either fludeoxyglucose-positron emission tomography [PET], computed tomography [CT] scan/magnetic resonance imaging [MRI] or bone scan) or measurable disease will be required; measurable disease is defined as at least one measurable lesion >= 10 mm on CT scan (15 mm for nodal lesions)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm or tumor cells in the blood >= 5 x 10^9/L; skin lesions can be used if the area is >= 2 cm in at least one diameter and photographed with a ruler
All lung lesions must be visible on computed tomography (CT) imaging
>= 1 measurable disease site on computed tomography (CT) scan or positron emission tomography (PET) (> 1.5 cm in longest dimension); (in select cases, for example extremity lesions, a magnetic resonance imaging [MRI] may be substituted)
Female patients with inoperable tumors or women with stage 4 disease diagnosed on computed tomography (CT), positron emission tomography (PET), PET/CT or bone scan
Histologically or cytologically confirmed pancreatic adenocarcinoma that has metastatic disease measurable by computed tomography (CT), magnetic resonance imaging (MRI), or (positron emission tomography (PET)
Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring 1.5 cm or larger
Tumor is not clearly shown on a computed tomography (CT) scan
Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT)
A subject with metastatic CRPC must have bone metastases accessible for biopsy by computed tomography (CT) guidance
Patients must have measurable disease on the 3D planning computed tomography (CT)
Measurable disease by computed tomograph (CT)/ and/or positron-emission tomography CT (PET-CT)
Patients should have measurable disease defined as a minimum of one tumor measuring >= 10 mm on computed tomography (CT) scans
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with computed tomography (CT) scan, positron emission tomography (PET) CT, or magnetic resonance imaging (MRI) exam
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans
Measurable or assessable disease defined as at least one of the following:            \r\n* A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by computed tomography (CT) portion of positron emission tomography (PET)/CT scan, CT scan, or magnetic resonance imaging (MRI)\r\n* Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
Measurable disease (at least 1 lesion of >= 1.5 cm in diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
Computed tomography (CT) of the neck to confirm staging
Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism
Scheduled for low dose computed tomography (CT) screening for lung cancer
Presence of cT1 renal mass by diagnostic computed tomography (CT) assessment
After completion of radiotherapy, within the last 12 months, a positron emission tomography (PET)/computed tomography (CT) or contrast-enhanced CT scan must be performed within 8 weeks of registration demonstrating no evidence of disease or loco-regional recurrence
Referred for computed tomography (CT) guided biopsy of lung lesion
Measurable disease >= 1.5 cm as measured on positron emission tomography (PET)-computed tomography (CT) scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 28 days prior to start of protocol therapy; the CT from a combined positron emission tomography (PET)/CT may be used if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease
Measurable disease (or nonmeasurable bone-only disease) assessed by computed tomography (CT) or positron emission tomography (PET)/CT, performed as part of standard of care, at the discretion of the attending oncologist
Willing and able to undergo low dose computed tomography (CT) scan, as determined by radiology team, or has had a lung cancer screen within 30 days of enrollment into this protocol.
Bone lesions (1 or more osteolytic lesions on low-dose whole body computed tomography [LDCT], positron-emission tomography with computed tomography [PET-CT] or CT)
Have a measurable lesion in the pelvis or abdomen, at a minimum of 0.5 cm in diameter on standard of care pre-operative imaging studies (computed tomography [CT], magnetic resonance imaging [MRI] or positron emission tomography [PET] scan)
Subject must have been referred for a clinically indicated PET-computed tomography (CT)
Patients who have a history of serious adverse events related to a previous MRI or PET/computed tomography (CT)
Inability to undergo or cooperate with PET/computed tomography (CT) scan (e.g., claustrophobia)
No clinical evidence of nodal disease (N1-N3) as assessed by CT and/or positron emission tomography (PET)/CT
Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan
Has measurable disease defined as ?1 lesion that can be accurately measured in ?2 dimensions with spiral computed tomography (CT) scan or combined CT/positron emission tomography (PET) scan. Minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis.
